GLP‑1s and muscle loss
- Experts now warn GLP‑1 weight‑loss drugs can reduce muscle mass, prompting calls for tailored nutrition. (nutritioninsight.com) - A review across 22 trials found semaglutide and tirzepatide produced the largest weight losses, while liraglutide remains more cost‑effective. (ajmc.com) - Food firms are designing high‑protein, nutrient‑dense concepts to help GLP‑1 users protect lean mass and digestion. (foodanddrinktechnology.com)
GLP-1 drugs help people eat less by slowing digestion and increasing fullness, but doctors and nutrition groups now say the weight lost can include muscle as well as fat. (nature.com) A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society said GLP-1 treatment trials show 5% to 18% body-weight loss, but also flagged muscle and bone loss, gastrointestinal side effects, high costs, and weight regain after discontinuation. (pmc.ncbi.nlm.nih.gov) That advisory told clinicians to screen diet, strength, function, and body composition at baseline and pair the drugs with aerobic activity, strength training, and nutrition support rather than relying on medication alone. (pmc.ncbi.nlm.nih.gov) The concern is body composition, not just the number on a scale: a 2025 Nature Reviews Endocrinology comment said rapid weight loss with glucagon-like peptide-1 receptor agonists can come at the cost of skeletal muscle, which can weaken metabolic and physical outcomes. (nature.com) A 2025 review in *Acta Diabetologica* said trial and real-world evidence “consistently” show lean body mass falls during GLP-1 therapy, a bigger issue for older adults and other patients already at risk of sarcopenia, the age- or illness-related loss of muscle and strength. (link.springer.com) The weight-loss leaders are still semaglutide and tirzepatide. An analysis of 22 randomized trials involving more than 40,000 adults, summarized by *The American Journal of Managed Care* in November 2025, found those drugs produced the largest losses in body weight, while liraglutide remained a lower-cost alternative as patent expiry approached. (ajmc.com) Cost arguments remain unsettled. A 2025 U.S. payer analysis in the *Journal of Managed Care & Specialty Pharmacy* found tirzepatide was the most cost-effective option over 68 weeks, ahead of oral semaglutide, injectable semaglutide, and liraglutide. (pmc.ncbi.nlm.nih.gov) Food companies are now building products around that muscle-loss risk and the appetite suppression these drugs cause. Arla Foods Ingredients said on April 20, 2026 that it had developed high-protein, nutrient-dense yogurt and shot concepts for GLP-1 users, with portions sized for reduced appetite and added cultures aimed at digestive comfort. (foodanddrinktechnology.com) Arla said its concepts include a 10-gram protein fermented shot in 70 milliliters, a 20-gram drinking yogurt in 200 milliliters, a 20-gram spoonable yogurt in 120 grams, and a 21-gram water-based protein shot in 100 milliliters. The company plans to show them at Vitafoods Europe in Barcelona from May 5 to 7, 2026. (foodanddrinktechnology.com) The shift in obesity care is no longer just about how much weight a drug can take off. It is increasingly about how much fat patients lose, how much muscle they keep, and whether nutrition and exercise can keep the tradeoff from getting worse. (nature.com)
